GET DAILY SIGNALSBSX vs MDT vs SYK: MedTech Earnings Preview as Q4 Results Put Growth and Margins in Focus
Key Takeaways
-
Boston Scientific (BSX) reports Q4 2025 earnings on February 4, with consensus expecting $0.78 adjusted EPS on $5.27B revenue, in line with guidance of $0.77–$0.79 EPS and 11–13% organic growth.
-
Medtronic (MDT) posted strong Q2 FY26 results: $9B revenue (+5.5% organic), $1.36 adjusted EPS, raising FY26 guidance amid pulsed field ablation momentum. Q3 FY26 results are expected February 17.
-
Stryker (SYK) delivered record Q4/FY 2025 results: $7.17B Q4 revenue (+11% organic), $4.47 adjusted EPS; FY sales topped $25B with 2026 guidance of 8–9.5% organic growth.
-
BSX leads in cardiovascular and MedSurg growth, while MDT and SYK focus on stable margins and capital equipment strength.
-
All three benefit from procedural volume recovery, though tariff headwinds (~$185–$400M impact) loom for 2026.
-
Investor focus: BSX’s strong beat history (~7% average) vs. peers’ raised outlooks signals competitive positioning.
Why This Comparison Matters
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
MDT’s ablation surge and SYK’s Mako robotics dominance illustrate trade-offs between growth and scale. Combined, the trio represents ~$300B in market capitalization, offering investors insight into cardiovascular, orthopedics, and surgical trends amid 8–10% industry growth forecasts.
BSX Earnings Focus
-
Revenue: $5.27B (+15.6% YoY, 11–13% organic per guidance)
-
Adjusted EPS: $0.78 (+11% YoY), within company guidance of $0.77–$0.79
-
Key drivers:
-
Cardiovascular (~65% revenue): FARAPULSE PFA, WATCHMAN FLX
-
MedSurg: Neuromodulation post-Axonix
-
U.S. revenue: ~$3.39B expected (+17%)
-
-
Other metrics: Margin pressure from tariffs, historical EPS beats ~7.36% average, FY25 EPS raised to $3.02–$3.04
-
Stock reaction: Historically +3–4% on positive surprises
MDT Earnings/Business Context
-
Q2 FY26 results: $9B revenue (+5.5% organic), $1.36 adjusted EPS (+8%)
-
Cardiac ablation: 71% growth (U.S. PFA +128%)
-
FY26 guidance: 5.5% organic revenue growth, EPS $5.62–$5.66
-
Margins: Adjusted gross margin +70bps to 65.9%
-
Risks: Tariff impacts (~$185M FY26), China VBP pressures
-
Outlook: Scale and diversification provide stability vs. BSX’s higher-growth trajectory
SYK Earnings/Business Context
-
Q4/FY 2025 results: $7.17B Q4 revenue (+11% organic), $4.47 adjusted EPS (+11.5%); FY $25.12B revenue (+10.3% organic), $13.63 EPS (+11.8%)
-
Margins: Adjusted operating margin +100bps to 26.3%; free cash flow 81% of adjusted net earnings
-
2026 guidance: 8–9.5% organic growth, $14.90–$15.10 EPS
-
Drivers: Mako robotics (orthopedics), double-digit MedSurg/Neuro growth, vascular pressures manageable
-
Risks: Tariffs (~$400M), supply chain, orthopedics competition
-
Positioning: Procedural and capital equipment focus contrasts BSX’s interventional emphasis
AI Trading Bot Perspective
Tickeron offers AI-driven trading bots for BSX, MDT, and SYK:
-
BSX bot: Trend Trader for Broad Market Optimal Financial Fusion (60min FA), targeting large-cap trend momentum
-
MDT bot: Corridor TP-SL 2 AI Agent (60min), optimized for channel-based entries/exits
-
SYK bot: Trend Trader for Beginners (60min TA), ideal for orthopedic momentum plays
Historical performance varies by market conditions; these bots provide automated signals to complement manual analysis.
Key DriversCardio & MedSurgCardio & scaleOrtho/Capital equipment
-
BSX: High-growth cardiovascular, potential upside from historical beats
-
MDT: Broad therapy stability, slower growth but reliable margins
-
SYK: Ortho/surgical dominance with strong margin expansion
-
Risks: BSX procedure-sensitive; MDT China & tariffs; SYK supply/ortho competition
Investor sentiment tilts BSX for growth, peers for stability, reflecting trade-offs between upside potential vs. steady execution.
Tickeron AI Verdict
Tickeron’s AI models currently favor BSX pre-earnings, citing:
-
Superior trend stability
-
15%+ organic trajectory
-
Historical EPS beat consistency
MDT and SYK provide lower-volatility, steady profiles, but BSX holds a probabilistic edge if guidance is reaffirmed and tariffs remain manageable.
Disclaimers and Limitations
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
BSX's RSI Indicator ascending out of oversold territory
The RSI Oscillator for BSX moved out of oversold territory on October 08, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 25 similar instances when the indicator left oversold territory. In 15 of the 25 cases the stock moved higher. This puts the odds of a move higher at 60%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for BSX just turned positive on November 09, 2026. Looking at past instances where BSX's MACD turned positive, the stock continued to rise in 22 of 46 cases over the following month. The odds of a continued upward trend are 48%.
BSX moved above its 50-day moving average on November 10, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +4.56% 3-day Advance, the price is estimated to grow further. Considering data from situations where BSX advanced for three days, in 200 of 336 cases, the price rose further within the following month. The odds of a continued upward trend are 60%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 33 of 67 cases where BSX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 49%.
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BSX as a result. In 51 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 56%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BSX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 54%.
BSX broke above its upper Bollinger Band on October 19, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for BSX entered a downward trend on October 14, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 55 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating fairly steady price growth. BSX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 66 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.485) is normal, around the industry mean (4.142). P/E Ratio (17.169) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.618) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (3.117) is also within normal values, averaging (40.124).
The Tickeron PE Growth Rating for this company is 95 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 96 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BSX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a maker of medical devices
Industry MedicalNursingServices
Advertisement